The exclusion criteria were: Previously diagnosed endometriosis, uterine leiomyomas, previous multiple surgeries, endocrinological disorders, and severe male factor infertility. Number Patient IUI İVF Pregnancy Term-Live Birth Clomiphene-1 Clomiphene-2 Clomiphene-3 Clomiphene-4 Letrozole-1 Letrozole-2 Letrozole-3 Follitropine-alfa 1 Follitropine-alfa 2 50 40 30 20 10 0 STUDY DESIGN The inclusion criteria were: Age between 20-39 years, basal FSH level < 10 mIU/ml, and body mass index<35 kg/m2. Patients who meet these criteria were included In the study program. One hundred thirty-six subfertile women who applied to the Obstetric and Gynecology Clinic at Bakırköy Sadikonuk Education and Research Hospital were allocated. Between February 2020 to January 2022, We accessed patient files from archive records. The patients were divided into two groups; use of clomiphene citrate (n=107) and letrozole (n=19). We gave follitropine alfa to some of the patients (n=19). LIVE PREGNANCY RATE AFTER OVULATION INDUCTION PROTOCOLS IN SECONDARY INFERTILE PATIENTS AUTHORS Mustafa Cengiz Dura1 Hilal Aktürk1 Murat Ekin2 AFFILIATIONS Bakırköy Sadikonuk 1Education and Research Hospital INTRODUCTION Ovulation induction protocols, including Clomiphene Citrate(Serm), GnRH analogs (GnRH agonist and antagonist), and Letrozole(aromatase inhibitor), are known and enumerated. Our study is cross-sectional and retrospective and obtained from the patients who applied to the infertility outpatient clinic and the hospital database between February 2020 to January 2022. RESULTS/FINDINGS OBJECTIVE İn this study, we aimed to investigate live pregnancy rates after variable ovulation induction protocols in secondary infertile patients. ANALYSIS CONCLUSION Our data found no significant difference in comparing ovulation induction protocols in live pregnancy at term. PARAGRAPH METNİNİZ It results in term pregnancy after ovulation induction; in secondary infertile patients. A significant relationship exists between previous pregnancies and live- term birth rates (p<0.05). At the same time, there is no significant relationship in live pregnancy after using clomiphene citrate, letrozole, and follitropine-alfa for ovulation induction. In our research, we use one after another Clomiphene Citrate first attempt (n=48) 38.1%, Clomiphene Citrate second attempt (n=42) 33.3%, Clomiphene Citrate third attempt (n=14) 11.1%, and Clomiphene Citrate fourth attempt (n=3) 2.4% rates. In another group, they take after another Letrozole first attempt (n=11) 8.7%, Letrozole second attempt (n=5) 4.0%, and Letrozole third attempt (n=3) %2.4 Nineteen patients take Follitropine-alfa .19 out of 16 patients take Letrozole after that; they take Follitropine-alfa when there is no adequate response; simultaneously, 107 out of 3 patients take Clomiphene Citrate after that; they take Follitropine-alfa. There was no significant difference between the groups in measurements after term delivery, marriage duration, infertility period, anti-mullerian hormone, follicular stimulating hormone, and spermiogram evaluation (p>0.05). TSRM 2022 10.ÜREME SAĞLIĞI VE İNFERTİLİTE KONGRESİ 10-13.KASIM 2022 GİRNE/KKTC Chart-1:Comparison of ovulation induction protocols in terms of live pregnancy at term. Figure-1:Comparison of ovulation induction protocols Total Number of Patient Number of secondary infertile patients Live pregnancy at term 136 126 29